Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)

• Company Description    Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $44.07 Daily Weekly Monthly 20 Day Moving Average: 139,560 shares Shares Outstanding: 24.03 (millions) Market Capitalization: $1,059.22 (millions) Beta: 1.11 52 Week High: $68.29 52 Week Low: $28.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.90% -22.09% 12 Week -15.40% -8.20% Year To Date -24.68% -10.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER - LEXINGTON,MA 02421 USA ph: 617-314-6297 fax: - mbiega@soleburytrout.com http://www.kerostx.com

• General Corporate Information    Officers Jasbir Seehra - Chief Executive Officer Keith Regnante - Chief Financial Officer Carl Gordon - Director Mary Ann Gray - Director Julius Knowles - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 492327101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 24.03 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $1,059.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.74 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -48.53% vs. Previous Quarter: -236.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -29.13 12/31/21 - -24.85 09/30/21 - -25.92 ROA 03/31/22 - -27.83 12/31/21 - -23.82 09/30/21 - -24.98 Current Ratio 03/31/22 - 19.85 12/31/21 - 21.23 09/30/21 - 20.52 Quick Ratio 03/31/22 - 19.85 12/31/21 - 21.23 09/30/21 - 20.52 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -323.80 12/31/21 - -282.25 09/30/21 - -62,468.00 Book Value 03/31/22 - 9.30 12/31/21 - 10.39 09/30/21 - 9.34 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©